Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity

Journal of Hypertension

Volumn 22, Issue 10, 2004, Pages 1867-1868

  Kingston, Richard ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ANGIOTENSIN; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; CELL SIZE; CELL STRUCTURE; EDITORIAL; HUMAN; HUMAN CELL; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; METABOLIC SYNDROME X; NONHUMAN; PRIORITY JOURNAL; PROADIPOCYTE; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 5044240148     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200410000-00006     Document Type: Editorial

References (14)

1. Verdecchia P, Reboldi G, Angeli F, Borgioni C, Gattobigio R, Filipucci L, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004; 43:963-969.
2. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPP) randomised trial. Lancet 1999; 353:611-616.
3. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003.
4. Vermes E, Ducharme A, Bourassa MG, Lessard M, White M, Tardif J-C. Enalapril reduces the incidence of diabetes in patients with chronic heart failure. Insight from studies of left ventricular dysfunction (SOLVD). Circulation 2003; 107:1291-1296.
5. Yusuf S, Gerstein H, Hoogwerf B, Pogue J, Bosch J, Bruce HR, et al. Ramipril and the development of diabetes. JAMA 2001; 286:1882-1885.
6. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363:2022-2031.
7. Furuhashi M, Nobuyuki U, Takizawa H, Yoshida D, Miniwa N, Murakami H, et al. Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity. J Hypertens 2004; 22:1977-1982.
8. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257:79-83.
9. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nature Med 2001; 7:947-953.
10. Ruan H, Lodish HF. Insulin resistance in adipose tissue: direct and indirect effects of tumour necrosis factor-α. Cytokine Growth Factor Rev 2003; 14:447-455.
11. Klein S, Fontana L, Young VL, Coggan AR, Kilo C, Patterson BW, et al. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med 2004; 350:2549-2557.
12. Janke J, Engeli S, Gorzelniak K, Luft FC, Sharma AM. Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. Diabetes 2002; 51:1699-1707.
13. Sharma AM, Janke J, Gorzelniak K, Engeli S, Luft FC. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 2002; 40:609-611.
14. Tomiyama H, Kushiro T, Abeta H, Ishii T, Takahashi A, Furukawa L, et al. Kinins contribute to the improvement of insulin sensitivity during treatment with angiotensin converting enzyme inhibitor. Hypertension 1994; 23:450-455.